OUTCOME OF BOARD MEETING

Related-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹18.50

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.1% vs market

Pharmaceuticals peers, median of 147sector-0.1%+0.1% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.1-0.1-0.1+0.1

Next day

+4.3-0.2+4.5-0.3+4.6

+8.9+0.3+8.6-0.3+9.2

+5.4+0.9+4.6+0.0+5.4

+5.4+0.8+4.6+0.0+5.4

+5.1+2.2+3.0+0.6+4.5

+3.2+3.4-0.1+1.4+1.8

15d

+1.7-0.8+2.5-3.0+4.8

+26.8+2.9+23.9+0.2+26.6

+13.0+0.8+12.1-0.5+13.5

+38.6+0.0+38.6-3.4+42.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board of Beryl Drugs Ltd met on 30 May 2025 and approved the audited financial results for the quarter and year ended 31 March 2025, along with the audited Balance Sheet, Profit & Loss statement, and Cash Flow statement. The board also noted the statutory auditor's report for FY 2024-25 and approved a related party transaction. Additionally, Abhay Bhandari & Associates, Chartered Accountants, was appointed as Internal Auditor for FY 2025-26, and Mr. Sudhir Sethi was authorised as the signing authority for tender-related documents for the year.

Likely market impact

Routine annual results approval with a related party transaction flagged for shareholder attention; investors should review the FY25 results and the nature of the related party transaction for any governance concerns.